Affordable Access

deepdyve-link
Publisher Website

Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching.

Authors
  • Cantini, Fabrizio1
  • Benucci, Maurizio2
  • 1 Department of Rheumatology, Azienda USL Toscana Centro, Hospital of Prato, Prato, Italy [email protected] , (Italy)
  • 2 Rheumatology Clinic, Azienda USL Toscana Centro, Nuovo S Giovanni di Dio Hospital, Florence, Italy. , (Italy)
Type
Published Article
Journal
Annals of the Rheumatic Diseases
Publisher
BMJ
Publication Date
Feb 01, 2020
Volume
79
Issue
2
Identifiers
DOI: 10.1136/annrheumdis-2018-214757
PMID: 30487149
Source
Medline
Keywords
Language
English
License
Unknown
Report this publication

Statistics

Seen <100 times